Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions

Interview with the Innovators
Videos — July 20, 2021

Featuring:

Ezra Cohen, MD, FRCPSC, FASCO
Professor of Medicine
Chief
Division of Hematology/Oncology
UC San Diego
La Jolla, CA
Mary Jo Fidler, MD
Associate Professor and Section Chief
Medical Oncology
Rush University Medical Center
Chicago, IL
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Enterprise Medical Director of Research
Comprehensive Care and Research Center
Philadelphia, PA
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes.

Related Articles

Importance of Hospital Partnerships for Bispecific Agent Implementation
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma
Videos
Read Article
EHR Implementation of Bispecific Agents for Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma, Bispecific Antibodies
Videos
Read Article
Total Cost of Care for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
Clinical Pathways in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Payer Policy Development for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
REMS Operational Considerations
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Adopting Bispecific Agents for Multiple Myeloma into Practice
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Team Education for Bispecific Usage in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
Transitions of Care in Multiple Myeloma Patients
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?